News

UCSF Team at 2022 Multidisciplinary NET Medical Symposium

UCSF representation at the 2022 Multidisciplinary NET Medical Symposium October 27-29 in Washington, D.C.

Claire Mulvey, MD receives Spring 2022 RAP Funding for eNet Study

Claire Mulvey, MD, Assistant Professor of Medicine, UCSF, received funds from the Spring 2022 Research Allocation Project (RAP) for her project "eNET: a Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors."

New eNET Study Open

eNET is a study to test the effectiveness of a Web-based program to collect information about symptoms, lifestyle, quality of life, and well-being for patients with neuroendocrine tumors. It is being run by Dr. Emily Bergsland and doctors at UCSF. To learn more or sign up, go to enet.…

UCSF NorCal CarciNET: What to Expect in Treatment

March 3, 2021

NorCal CarciNET Virtual Meeting | Nov 4, 2020

 

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

Charles Ryan invites Rahul Aggarwal to discuss treatment-emergent small-cell neuroendocrine prostate cancer, an area not well characterized in the era of modern androgen receptor (AR)-targeting therapy.  

NETRF funds $3.5 million in research to advance neuroendocrine tumor treatment

UCSF's Claire Mulvey, MD, has been awarded a Fellowship Award from the Neuroendocrine Tumor Research Foundation (NETRF) for her project "Trends in incidence and survival outcomes for lung NETs."  The Neuroendocrine Tumor Research Foundation (NETRF), Boston, MA, today announced $3.5 million in…

PET offers more precise screening method to select candidates for radionuclide therapy

A new study published in The Journal of Nuclear Medicine evaluated the role of 68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in selecting neuroendocrine tumor patients who may benefit from peptide receptor radionuclide therapy (PRRT).

2019 Neuroendocrine Tumor Patient Conference

Presented by the UCSF Helen Diller Family Comprehensive Cancer Center and NorCal CarciNET Community, in collaboration with Stanford University and with generous support provided by supporters and industry partners. Co-Host: NorCal CarciNET Community  Sunday, February 10, 2019 at 8:30am …

NETRF Announces $2.5 Million in Research to Advance the Treatment of Neuroendocrine Tumors

(Boston, MA) — The Neuroendocrine Tumor Research Foundation (NETRF) continues its aggressive funding of neuroendocrine cancer research with eight new grants totaling $2.5 million. With this newest round of funding, NETRF expands its portfolio to include research into lung neuroendocrine tumors (…